Stock Events

Stock Events

ImmunityBio 

$8.08
482
-$0.11-1.34% 19:59 Today
+$0.00+0%21:48After hours

Statistics

Day High
8.24
Day Low
8.01
52W High
12.43
52W Low
1.95
Volume
4,316,596
Avg. Volume
10,250,563
Mkt Cap
8.56B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.62
-0.44
-0.25
-0.07
Expected EPS
-0.07
Actual EPS
N/A

Financials

-310.18%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
113.29MRevenue
-351.4MNet Income

Analyst Ratings

16.67Average Price Target
The highest estimate is 23.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IBRX. It's not an investment recommendation.
NVIDIA
76
NVDA
Amazon
64
AMZN
Microsoft
62
MSFT
Alphabet
53
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap55.09B
Moderna is a leader in mRNA technology, directly competing in the development of vaccines and therapeutics, areas where ImmunityBio is also active.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech, similar to Moderna, specializes in mRNA technology for developing vaccines, including for COVID-19, competing with ImmunityBio's efforts in vaccine development.
Novavax
NVAX
Mkt Cap1.53B
Novavax is a competitor in the vaccine space, particularly for COVID-19, where ImmunityBio also aims to make an impact.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a large pharmaceutical company with a broad portfolio that includes vaccines and cancer treatments, areas where ImmunityBio is also involved.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the development of vaccines and oncology treatments, overlapping with ImmunityBio's focus areas.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is involved in developing vaccines and treatments for various diseases, including cancer, directly competing with ImmunityBio's research and development efforts.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company that focuses on antiviral drugs and cancer therapies, competing with ImmunityBio in the oncology and infectious disease sectors.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on human therapeutics, including oncology and cardiovascular diseases, areas where ImmunityBio is also seeking to make advancements.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is known for its work in immunology and oncology, directly competing with ImmunityBio's efforts in developing immune-based therapies.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company that operates in various therapeutic areas, including oncology and vaccines, making it a competitor to ImmunityBio.

About

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Show more...
CEO
Richard Gerald Adcock
Employees
691
Country
United States
ISIN
US45256X1037
WKN
000A2QQ2E

Listings

XNAS
US
IBRX
XETRA
DE
26CA.XETRA
F
DE
26CA.F
MU
DE
26CA.MU

0 Comments

Share your thoughts

FAQ

What is ImmunityBio stock price today?▼
The current price of IBRX is $8.08 USD — it has decreased by -1.34% in the past 24 hours. Watch ImmunityBio stock price performance more closely on the chart.
What is ImmunityBio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange ImmunityBio stocks are traded under the ticker IBRX.
Is ImmunityBio stock price growing?▼
IBRX stock has risen by +0.37% compared to the previous week, the month change is a +16.26% rise, over the last year ImmunityBio has showed a +238.08% increase.
What is ImmunityBio market cap?▼
Today ImmunityBio has the market capitalization of 8.56B
When is the next ImmunityBio earnings date?▼
ImmunityBio is going to release the next earnings report on November 05, 2026.
What were ImmunityBio earnings last quarter?▼
IBRX earnings for the last quarter are -0.22 USD per share, whereas the estimation was -0.08 USD resulting in a -175% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is ImmunityBio revenue for the last year?▼
ImmunityBio revenue for the last year amounts to 113.29M USD.
What is ImmunityBio net income for the last year?▼
IBRX net income for the last year is -351.4M USD.
How many employees does ImmunityBio have?▼
As of September 04, 2026, the company has 691 employees.
In which sector is ImmunityBio located?▼
ImmunityBio operates in the Health & Wellness sector.
When did ImmunityBio complete a stock split?▼
ImmunityBio has not had any recent stock splits.
Where is ImmunityBio headquartered?▼
ImmunityBio is headquartered in SAN DIEGO, United States.